» Articles » PMID: 27648319

Acute and Fatal Isoniazid-Induced Hepatotoxicity: A Case Report and Review of the Literature

Overview
Publisher Wiley
Date 2016 Sep 21
PMID 27648319
Citations 6
Authors
Affiliations
Soon will be listed here.
Abstract

This paper describes a case of an acute and fatal isoniazid-induced hepatotoxicity and provides a review of the literature. A 65-year-old female diagnosed with latent Mycobacterium tuberculosis infection was receiving oral isoniazid 300 mg daily. She was admitted to the hospital for epigastric and right sided flank pain of one-week duration. Laboratory results and imaging confirmed hepatitis. After ruling out all other possible causes, she was diagnosed with isoniazid-induced acute hepatitis (probable association by the Naranjo scale). After discharge, the patient was readmitted and suffered from severe coagulopathy, metabolic acidosis, acute kidney injury, hepatic encephalopathy, and cardiorespiratory arrest necessitating two rounds of cardiopulmonary resuscitation. Despite maximal hemodynamic support, the patient did not survive. A review of the literature, from several European countries and the United States of America, revealed a low incidence of mortality due to isoniazid-induced hepatotoxicity when used as a single agent for latent Mycobacterium tuberculosis infection. As for the management, the first step consists of withdrawing isoniazid and rechallenge is usually discouraged. Few treatment modalities have been proposed; however there is no robust evidence to support any of them. Routine monitoring for hepatotoxicity in patients receiving isoniazid is warranted to prevent morbidity and mortality.

Citing Articles

Ionic resorcinarenes as drug solubilization agents in water.

Osei F, Twum K, Manfredi B, Fatohi M, Bessem Ojong Y, Washington V RSC Adv. 2024; 14(46):34228-34238.

PMID: 39469002 PMC: 11514725. DOI: 10.1039/d4ra06682k.


Treatment of Psoriasis Patients with Latent Tuberculosis Using IL-17 and IL-23 Inhibitors: A Retrospective, Multinational, Multicentre Study.

Torres T, Chiricozzi A, Puig L, Le A, Marzano A, Dapavo P Am J Clin Dermatol. 2024; 25(2):333-342.

PMID: 38265746 PMC: 10867072. DOI: 10.1007/s40257-024-00845-4.


Isoniazid-Induced Acute Liver Failure Requiring Liver Transplantation.

Almeida M, Gomes F, Ginga M, Fernandes M, Cartucho J Cureus. 2023; 14(12):e32905.

PMID: 36699772 PMC: 9870068. DOI: 10.7759/cureus.32905.


An Investigation of the Risk Factors Associated With Anti-Tuberculosis Drug-Induced Liver Injury or Abnormal Liver Functioning in 757 Patients With Pulmonary Tuberculosis.

Zhong T, Fan Y, Dong X, Guo X, Wong K, Wong W Front Pharmacol. 2021; 12:708522.

PMID: 34819852 PMC: 8606396. DOI: 10.3389/fphar.2021.708522.


Identifying gaps in the quality of latent tuberculosis infection care.

Hannah A, Dick M J Clin Tuberc Other Mycobact Dis. 2020; 18:100142.

PMID: 31956699 PMC: 6957813. DOI: 10.1016/j.jctube.2020.100142.


References
1.
Nolan C, Goldberg S, Buskin S . Hepatotoxicity associated with isoniazid preventive therapy: a 7-year survey from a public health tuberculosis clinic. JAMA. 1999; 281(11):1014-8. DOI: 10.1001/jama.281.11.1014. View

2.
Kaplowitz N . Drug-induced liver injury. Clin Infect Dis. 2004; 38 Suppl 2:S44-8. DOI: 10.1086/381446. View

3.
Haber E, Osborne R . Icterus and febrile reactions in response to isonicotinic acid hydrazine; report of two cases and review of the literature. N Engl J Med. 1959; 260(9):417-20. DOI: 10.1056/NEJM195902262600904. View

4.
Millard P, Wilcosky T, Weber D . Isoniazid-related fatal hepatitis. West J Med. 1996; 164(6):486-91. PMC: 1303623. View

5.
Kramer M, Hutchinson T . The Yale algorithm. Special workshop--clinical. Drug Inf J. 1983; 18(3-4):283-91. DOI: 10.1177/009286158401800315. View